Skip to content

Study · Randomized controlled trial · n = 136 · 1998

6 results

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.

Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Mar 1998Cited by 118 (Europe PMC)

PMID9508182 (opens in a new tab)DOI10.1200/jco.1998.16.3.994 (opens in a new tab)PepBankPUB-09508182
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with receptor-positive metastatic breast cancer, failure-free survival was similar with goserelin and ovariectomy.

    In plain wordsIn premenopausal women with metastatic breast cancer, failure-free survival was similar with goserelin and ovariectomy.

    Peptide
    Goserelin
    Outcome
    No significant changeFailure-free survival
    Study

    n = 136

    Comparator
    Surgical ovariectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 4 weeks · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    FFS and OS were similar for goserelin and ovariectomy.
    2 context sentences
    Summary · context
    Between August 1, 1987 and July 15, 1995 138 (136 eligible) premenopausal patients with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive metastatic breast cancer were entered by the Southwest Oncology Group (SWOG), North Central Cancer Treatment Group (NCCTG), and Eastern Cooperat…
    Summary · context
    Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69) versus surgical ovariectomy (n = 67).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with metastatic breast cancer, overall survival was similar with goserelin and ovariectomy; the death hazard ratio was .80.

    In plain wordsIn premenopausal women with metastatic breast cancer, overall survival was similar with goserelin and ovariectomy.

    Peptide
    Goserelin
    Outcome
    No significant changeOverall survival
    Study

    n = 136

    Comparator
    Surgical ovariectomy
    Outcome group
    Mortality · Cancer
    Studied dose
    3.6 mg every 4 weeks · subcutaneousAs given in this study (human).

    Measurements

    Death hazard ratio
    0.8 ratio
    goserelin versus ovariectomy
    Death hazard ratio confidence interval
    0.53 to 1.2 95% CI
    goserelin versus ovariectomy

    Source sentences

    Summary
    The goserelin/ovariectomy death hazards ratio was .80 and the associated 95% confidence interval (CI) was .53 to 1.20.
    3 context sentences
    Summary · context
    FFS and OS were similar for goserelin and ovariectomy.
    Summary · context
    Between August 1, 1987 and July 15, 1995 138 (136 eligible) premenopausal patients with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive metastatic breast cancer were entered by the Southwest Oncology Group (SWOG), North Central Cancer Treatment Group (NCCTG), and Eastern Cooperat…
    Summary · context
    Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69) versus surgical ovariectomy (n = 67).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with metastatic breast cancer, the test of 50% survival improvement with ovariectomy over goserelin was rejected (P = .006).

    In plain wordsIn premenopausal women with metastatic breast cancer, the test of 50% survival improvement with ovariectomy over goserelin was rejected.

    Peptide
    Goserelin
    Outcome
    Not applicableExclusion of survival advantage from ovariectomy
    Study

    n = 136

    Comparator
    Surgical ovariectomy
    Outcome group
    Mortality · Cancer
    Studied dose
    3.6 mg every 4 weeks · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The test of 50% improvement in survival due to ovariectomy was rejected at P = .006.
    2 context sentences
    Summary · context
    Between August 1, 1987 and July 15, 1995 138 (136 eligible) premenopausal patients with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive metastatic breast cancer were entered by the Southwest Oncology Group (SWOG), North Central Cancer Treatment Group (NCCTG), and Eastern Cooperat…
    Summary · context
    Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69) versus surgical ovariectomy (n = 67).
  4. 04HumanRandomized controlled trialSafety outcome

    In premenopausal women with metastatic breast cancer, hot flashes occurred in 75% with goserelin versus 46% with ovariectomy.

    In plain wordsIn premenopausal women with metastatic breast cancer, hot flashes were more common with goserelin than ovariectomy.

    Peptide
    Goserelin
    Outcome
    IncreaseHot flashes
    Study

    n = 136

    Comparator
    Surgical ovariectomy
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    3.6 mg every 4 weeks · subcutaneousAs given in this study (human).

    Measurements

    Hot flashes
    75%
    goserelin
    Hot flashes
    46%
    ovariectomy

    Source sentences

    Summary
    Hot flashes (75% v 46%) and tumor flare (16% v 3%) were more common with goserelin.
    2 context sentences
    Summary · context
    Between August 1, 1987 and July 15, 1995 138 (136 eligible) premenopausal patients with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive metastatic breast cancer were entered by the Southwest Oncology Group (SWOG), North Central Cancer Treatment Group (NCCTG), and Eastern Cooperat…
    Summary · context
    Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69) versus surgical ovariectomy (n = 67).
  5. 05HumanRandomized controlled trialSafety outcome

    In premenopausal women with metastatic breast cancer, tumor flare occurred in 16% with goserelin versus 3% with ovariectomy.

    In plain wordsIn premenopausal women with metastatic breast cancer, tumor flare was more common with goserelin than ovariectomy.

    Peptide
    Goserelin
    Outcome
    IncreaseTumor flare
    Study

    n = 136

    Comparator
    Surgical ovariectomy
    Outcome group
    Adverse events · Cancer
    Studied dose
    3.6 mg every 4 weeks · subcutaneousAs given in this study (human).

    Measurements

    Tumor flare
    16%
    goserelin
    Tumor flare
    3%
    ovariectomy

    Source sentences

    Summary
    Hot flashes (75% v 46%) and tumor flare (16% v 3%) were more common with goserelin.
    2 context sentences
    Summary · context
    Between August 1, 1987 and July 15, 1995 138 (136 eligible) premenopausal patients with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive metastatic breast cancer were entered by the Southwest Oncology Group (SWOG), North Central Cancer Treatment Group (NCCTG), and Eastern Cooperat…
    Summary · context
    Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69) versus surgical ovariectomy (n = 67).
  6. 06HumanNon-randomized trialEfficacy outcome

    In premenopausal women with metastatic breast cancer, goserelin lowered serum estradiol to postmenopausal levels.

    In plain wordsIn premenopausal women with metastatic breast cancer, goserelin lowered serum estradiol to postmenopausal levels.

    Peptide
    Goserelin
    Outcome
    DecreaseSerum estradiol
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.6 mg every 4 weeks · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Goserelin lowered serum estradiol to postmenopausal levels.
    2 context sentences
    Summary · context
    Between August 1, 1987 and July 15, 1995 138 (136 eligible) premenopausal patients with estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive metastatic breast cancer were entered by the Southwest Oncology Group (SWOG), North Central Cancer Treatment Group (NCCTG), and Eastern Cooperat…
    Summary · context
    Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69) versus surgical ovariectomy (n = 67).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.